Navigation Links
Two New Strategic Reports Expand Coverage Of BioTrend's Biosimilars Advisory Service

EXTON, Pa., April 1, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released two strategic components to its 2013 Biosimilars Advisory Service, which provides vital business planning insights and analysis in the evolving biosimilars space. The reports entitled Corporate Strategies and Global Pipelines, Pathways and Key Stakeholder Perspectives of Biosimilars analyze surveyed opinions of specialist physicians and payers in the United States and Europe and secondary market research to uncover critical trends in strategic development for commercially lucrative market segments.

"The Biosimilars Advisory Service has always been a highly valuable tool for understanding trends in a complex and dynamic market," said Andrew Merron , Ph.D., Senior Director, Biosimilars Research at Decision Resources Group. "These new reports aim to enhance the overall service by evaluating current market opinion to help understand globally focused business strategies, regulatory guidance in multiple markets and pipeline information."

BioTrends Research Group's Biosimilars Advisory Service also includes quarterly webinars detailing major industry developments, analyst insight addressing key market changes, therapeutic area-specific primary research and interactive annualized 10-year forecasts.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 For more information, contact:BioTrends Research Group Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuro Intervention Market: New Strategic Landscape & Market Forecast
2. MDHI Receives Strategic Investment to Continue Strong Growth - Moves into Positive Operating Cash Flow for March 2013 Quarter
3. Saladax Biomedical Receives $22.4 Million Strategic Equity Investment From Shanghai Fosun Pharmaceutical
4. DDS Lab Announces Strategic Alliance with United Concordia
5. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
6. Evofem Announces Strategic Alliance with WomanCare Global
7. WebMD and Qualcomm Life Launch Strategic mHealth Collaboration
8. Imalux Corporation Engages Advisor to Explore Strategic Options
9. BioDrain Medical Retains KCSA Strategic Communications as Corporate Communications Counsel
10. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
11. Covaris and HORIBA Instruments Form Strategic Relationship
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
Breaking Medicine Technology:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... States, today announced that its iconic bottle has won top honors in Beverage World ... The Company also announced that it has been selected as a 2015 U.S.A. ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
Breaking Medicine News(10 mins):